Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome by Ohanian, Maro et al.
© 2011 Ohanian et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Pharmacology: Advances and Applications 2011:3 5–12
Clinical Pharmacology: Advances and Applications Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
5
CAse rePOrT
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CPAA.S17904
eculizumab safely reverses neurologic impairment 
and eliminates need for dialysis in severe atypical 
hemolytic uremic syndrome
Maro Ohanian
Christian Cable
Kathleen Halka
Department of Hematology 
and Oncology, scott and White 
Healthcare, The Texas A&M  
Health science Center College  
of Medicine, Temple, TX, UsA
Correspondence: Maro Ohanian 
Department of Hematology and 
Oncology, scott and White Healthcare, 
2401 south 31st street, Temple,  
TX 76508, UsA 
Tel +1 281 217 1974 
Fax +1 254 771 4890 
email ohanianus@yahoo.com
Abstract: This case report describes how eculizumab reversed neurologic impairment and 
improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, 
after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, 
and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed 
ischemic colitis with scattered mesenteric microthrombi. Due to mental and respiratory decline, 
she remained intubated. Continuous venovenous hemodialysis was initiated. Renal failure, 
neurologic changes, hemolysis, thrombotic microangiopathy, and low complement levels 
all suggested atypical hemolytic uremic syndrome. Eculizumab 900 mg was administered 
intravenously on hospital day 6 and continued weekly for four doses followed by maintenance 
therapy. She recovered neurologically and renally after the third dose, and hematologically by 
the sixth dose. Her recovery has been sustained on long-term eculizumab treatment. In severe 
atypical hemolytic uremic syndrome, eculizumab safely reverses neurologic impairment and 
eliminates the need for dialysis. The optimal duration of treatment with eculizumab remains 
to be determined.
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Introduction
Atypical hemolytic uremic syndrome involves congenital or acquired dysregulation 
of the alternative complement pathway. Uncontrolled chronic systemic complement 
activation causes inflammation and thrombotic microangiopathy. Dysfunctional 
alternative complement pathway activation reduces host cell protection and results 
in inappropriate complement activation of platelets and endothelial cells.1,2 Atypical 
hemolytic uremic syndrome can cause multiorgan failure and severe neurologic 
changes. We present a case of severe atypical hemolytic uremic syndrome with 
  significant neurologic damage amidst multiorgan failure, including severe renal failure. 
Terminal complement inhibition with eculizumab safely reversed the neurologic 
changes and eliminated the need for dialysis. While eculizumab is not yet approved 
by the US Food and Drug Administration for atypical hemolytic uremic syndrome, 
this case report is one of several illustrating its safety and efficacy.
Case report
A fifty-year-old female with a history of rheumatoid arthritis was   transferred to our 
intensive care unit with sepsis, pancolitis, acute renal failure, and thrombocytopenia. 
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abdominal pain. Her home medications included an estrogen 
patch, lansoprazole, and twice-weekly etanercept. Stool 
studies, including tests for Escherichia coli 0157:H7 and 
Clostridium difficile, were all negative. Prior to transfer, 
she was on ceftriaxone, ciprofloxacin, and dexamethasone 
for colitis. At our facility, she remained on broad-spectrum 
antimicrobials, including fluconazole, ciprofloxacin, metron-
idazole, and pipercillin-tazobactum. Because of her sepsis, 
she remained on adrenal support with methylprednisolone.
Her initial laboratory investigations revealed a count of 
12.7 gm/dL hemoglobin, white blood cells of 31.4 × 10e9/L, 
creatinine of 3.8 mg/dL, and platelets of 28 × 10e9/L. 
Coagulation studies did not suggest disseminated intravascular 
coagulation. Aspartate aminotransferase was elevated at 
118 U/L. Alanine aminotransferase was normal. Lactate 
dehydrogenase was 1199 units per liter (U/L). Haptoglobin 
was less than 6 mg/dL. Direct Coomb’s test was negative. 
Chest x-ray revealed bibasilar opacities and small bilateral 
pulmonary effusions. Reticulocyte count was 2.7%. Decreased 
complement levels were later noted: C3 was 35 (83–184) mg/
dL and C4 was 6 (17–59) mg/dL. ADAMTS13 activity was 
adequate at 63% (drawn prior to treatment). By hospital day 5, 
there were occasional schistocytes on the peripheral smear.
On the day of transfer, she underwent total abdominal 
colectomy with end ileostomy. During surgery she received 
2 units (U) of packed red blood cells, 2 U of fresh frozen 
plasma, and 2 U of pooled platelets. After surgery, her 
platelets rose, and continued to rise during the first five 
days of the admission, without additional transfusions. The 
rising platelets after colectomy suggested previous platelet 
consumption by a thrombotic microangiopathic process in 
the colon. This was later confirmed by the pathology report, 
which described diffuse ischemic colitis with scattered 
fibrin microthrombi along the mesentery, consistent with 
microangiopathy.
With mental and respiratory decline, she remained 
intubated. By hospital day 3, she did not respond to   commands 
and was generally unresponsive to voice and painful stimuli 
for the next 11 days. By hospital day 4, there were reports of 
seizure activity. A noncontrast computed tomography scan 
of the brain was unremarkable; she was too unstable to leave 
the intensive care unit for a magnetic resonance imaging scan 
of the brain. Electroencephalographic findings revealed no 
definite epileptiform activity, but were consistent with diffuse 
cerebral dysfunction.
As renal failure worsened, continuous venovenous 
hemodialysis was initiated on hospital day 4. Her clinical 
picture, with severe renal failure, profound neurologic 
changes, severe hemolysis, thrombotic microangiopathy, 
and low complement levels, were all suggestive of atypical 
hemolytic uremic syndrome. Because atypical hemolytic 
uremic syndrome is characterized by chronic uncontrolled 
systemic complement activation,2 the anti-C5 monoclonal 
antibody, eculizumab, was administered intravenously at a 
dose of 900 mg on hospital day 6. It was continued weekly 
for four doses, followed by maintenance therapy. Therapeutic 
plasma exchange was also administered for a few hours 
before her first dose of eculizumab. Because treatment with 
eculizumab increases the risk of infection with Neisseria 
meningitidis, the meningococcal vaccine was given prior to 
the first dose, and 14 days of ciprofloxacin was ordered for 
meningococcal prophylaxis.3
Four days after receiving her first dose of eculizumab, the 
patient’s lactate dehydrogenase dropped to 837 U/L and her 
complement levels rose: C3 rose to 81 (83–184) mg/dL and 
C4 rose to 16 (17–59) mg/dL, as shown in Figures 1 and 2. 
Seven days into treatment, she was opening her eyes, tracking, 
and localizing to painful stimuli. The day after her second 
dose, her lactate dehydrogenase decreased to 681 U/L. Two 
days after the second dose she was nodding appropriately, 
following commands, and interacting with her family. 
Three days after the second dose, her lactate dehydrogenase 
decreased to 498 U/L and her dialysis frequency was reduced 
to three times per week. Four days after her second dose of 
0
01 02 03 0
Time in days
LDH as a function of time
L
D
H
 
v
a
l
u
e
s
 
(
u
n
i
t
s
/
L
)
40 50 60 70
Value
Range
500
1000
1500
2000
2500
Figure 1 Lactate dehydrogenase (normal 108–202 U/L) shown as a function of 
time  (hospital  days).  Lactate  dehydrogenase  gradually  dropped  after  initiating 
treatment with eculizumab. eculizumab administration is denoted by vertical tick 
marks (hospital days 6, 13, 20, 27, 34, 48, and day 63). Four days after the first dose, 
lactate dehydrogenase dropped to 837 U/L. After the second dose of eculizumab 
on day 13, lactate dehydrogenase dropped to 556 U/L. A week after the third dose, 
lactate dehydrogenase was down to 349 U/L. Three days after the sixth dose, lactate 
dehydrogenase was normal. It did rise slightly before the seventh dose was due.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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eculizumab, she was ready to be weaned from the ventilator; 
within several days, she no longer required oxygen. A week 
after her third dose of eculizumab, her lactate dehydrogenase 
was down to 349 U/L (Figure 1).
Three days after her third dose, she was urinating up 
to 875 mL, and her cognition and memory had recovered 
to baseline. After the fourth dose of eculizumab, her urine 
output reached 1451 mL, and dialysis was discontinued. 
Three days after her sixth dose, her lactate dehydrogenase, 
haptoglobin, C3, and C4 were all normal (see Figures 1–5 
for a summary of treatment responses).
This patient presented with rapidly progressive atypical 
hemolytic uremic syndrome characterized by multiorgan 
failure, including severe neurologic decline. Her renal 
recovery was remarkable, and she has remained off dialysis 
with long-term eculizumab treatment. Additionally, her 
creatinine has continued to decrease off dialysis, with recent 
levels as low as 2.24 mg/dL (see Figure 3 for a summary of 
creatinine over time).
While renal failure is generally the most pronounced com-
plication of atypical hemolytic uremic syndrome, neurologic 
impairment can also occur in severe cases. Our patient’s 
rapid and profound neurologic deterioration appears to 
have resulted from significant thrombotic microangiopathy. 
Despite 11 days in the intensive care unit without mean-
ingful neurologic responses, the patient recovered total 
neurologic function after only a few doses of eculizumab. 
Her swift and complete neurologic recovery makes this case 
  particularly noteworthy. Twenty-six days after the first dose 
of eculizumab, a magnetic resonance imaging brain scan was 
performed upon request by the neurologist. The findings were 
consistent with a subacute right parietal lobe infarction with 
areas of hemorrhagic conversion. There was also a suspected 
tiny subacute infarct within the right centrum semiovale 
(Figure 6). Despite these findings, which suggest extensive 
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Figure 2 C3 (normal 83–184 mg/dL) shown as a function of time (hospital days). 
eculizumab administration is denoted by vertical tick marks (hospital days 6, 13, 20, 
27, 34, 48, and day 63). After the second dose of eculizumab on day 13, C3 rose   
to 81. Thirteen days after the sixth dose, C3 was normal and remained normal.
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Figure 3 Creatinine (normal 0.5–1.3 mg/dL) shown as a function of time (hospital 
days). eculizumab administration is denoted with vertical tick marks (hospital days 6, 
13, 20, 27, 34, 48, and day 63). The start and end dates of continuous venovenous 
hemodialysis are marked on the time axis by 2 carat (^) symbols (hospital days 4   
and 27). Three days after the second dose of eculizumab, dialysis frequency was 
reduced  to  three  times  per  week.  Continuous  venovenous  hemodialysis  was 
completely discontinued after the fourth dose of eculizumab. Despite a delayed and 
reduced dose of eculizumab at the seventh administration, creatinine continued to 
decrease to as low as 2.24 mg/dL.
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Figure 4 Haptoglobin shown as a function of time (hospital days). eculizumab 
administration is denoted by vertical tick marks (hospital days 6, 13, 20, 27, 34, 48, 
and days 63 and 69). Initial haptoglobin was ,6 (normal range 62–197) mg/dL. Five 
days after the third dose, haptoglobin was normal and remained normal until the 
time the seventh dose was due. Haptoglobin then dropped precipitously, indicating 
an ongoing need for the drug. Haptoglobin did increase again after the seventh dose 
on day 63, and later normalized to 71 mg/dL three days after receiving the eighth 
dose on day 69.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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thrombotic microangiopathic brain injury, she has recovered 
neurologically and remains stable.
The dosing schema used in this patient is similar to that 
used in the clinical trials of eculizumab in atypical hemolytic 
uremic syndrome. Maintenance therapy, starting on week 5, 
was planned to be 1200 mg every two weeks.4–6 Due to nausea 
at that dose, the seventh dose was delayed by one day because 
the patient refused it, but then agreed to a reduced dose 
of 600 mg weekly. With antiemetic premedications, there 
was no nausea. Nausea has been reported with eculizumab 
in up to 16% of cases.7 When the seventh dose was due, 
laboratory investigations suggested relapsing hemolysis, 
with haptoglobin ,6 mg/dL, indicating her continued need 
for the drug. As shown in Figure 4, the haptoglobin increased 
again after the seventh dose, and normalized to 71 mg/dL 
three days after the eighth dose. Her creatinine continued to 
improve despite the dose modification.
Discussion
Atypical versus typical hemolytic  
uremic syndrome
The annual incidence of Shiga toxin-positive hemolytic 
uremic syndrome is two cases per 100,000. The annual 
incidence of hemolytic uremic syndrome in adults in our 
patient’s age group, ie, 50–59 years, is approximately 
0.5 cases per 100,000.8,9 Shiga toxin-positive hemolytic 
uremic syndrome primarily affects children. In children 
under five years, the annual incidence reaches 6.1 cases per 
100,000. Of cases in children, 90% are caused by Shiga-like 
toxin-  producing E. coli or Shiga toxin-producing Shigella 
dysenteriae. This form of hemolytic uremic syndrome, 
  classified as typical or enteropathic hemolytic uremic 
  syndrome, involves diarrhea followed by acute renal failure. 
Streptococcus pneumoniae also causes a severe form of 
hemolytic uremic syndrome unrelated to Shiga or Shiga-like 
toxin-producing organisms.8,9
A minority of hemolytic uremic syndrome cases, gener-
ally unrelated to Shiga /Shiga-like toxin or S. pneumoniae, 
are termed atypical hemolytic uremic syndrome. Atypical 
hemolytic uremic syndrome accounts for approximately 
10% of pediatric hemolytic uremic syndrome cases and the 
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Figure 5 C4 (normal 17–59 mg/dL) shown as a function of time (hospital days). 
eculizumab administration is denoted by vertical tick marks (hospital days 6, 13, 20, 
27, 34, 48, and day 63). The day after the second dose of eculizumab on day 13, C4 
rose to 16. Three days after the sixth dose, C4 was normal and remained normal.
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majority of adult cases.8–10 The prevalence and incidence 
of atypical hemolytic uremic syndrome, a rare condition, 
is not well established.11 The estimated prevalence of 
atypical hemolytic uremic syndrome in European children 
under 18 years is approximately 3.3 per million.12 The 
prevalence in adults may be lower. The estimated overall 
annual incidence of atypical hemolytic uremic syndrome 
in the US is one in 500,000.13
The pathogenesis of atypical hemolytic uremic syndrome 
involves genetic or acquired alternative complement path-
way regulator deficiencies.8–10 In atypical hemolytic uremic 
syndrome, reduced C3 levels may sometimes be observed, 
further suggesting uncontrolled complement activation and 
consumption. Because the alternative complement pathway 
convertase requires cleavage of C3 and not C4, low serum 
C3 and normal C4 suggest selective alternative pathway 
activation.9,14
In typical hemolytic uremic syndrome, renal function is 
preserved in 75% of cases, whereas the majority of patients 
with atypical hemolytic uremic syndrome develop end-stage 
renal disease or die.8,9,15,16 In the acute phase of hemolytic 
uremic syndrome, mortality is 3%–5%. In contrast, atypical 
hemolytic uremic syndrome has a significantly worse prog-
nosis, with a mortality of up to 25% in the acute phase.8,9,14
Under 20% of atypical hemolytic uremic syndrome 
cases are familial. The rest are considered to be sporadic, 
and are triggered by a variety of pathologies, including 
human immunodeficiency virus, chemotherapeutic agents, 
immunotherapeutic agents, antiplatelet agents, cancer, 
transplant, and pregnancy. In the post-transplant setting, 
de novo hemolytic uremic syndrome has been associated 
with calcineurin inhibitors (cyclosporine [5%–15%], 
tacrolimus [1%]), and humoral rejection. Approximately 
50% of   sporadic cases of atypical hemolytic uremic 
syndrome show no obvious cause and are considered 
idiopathic.8,9
Prodromic diarrhea has often been used to distinguish 
typical from atypical hemolytic uremic syndrome. Our case 
of atypical hemolytic uremic syndrome demonstrates how 
prodromic diarrhea alone cannot be used to distinguish these 
two conditions. Approximately 20%–30% of atypical hemo-
lytic uremic syndrome cases involve prodromic diarrhea.14 
Although our patient’s stool studies did not reveal any Shiga 
or Shiga-like toxin-producing organisms, these organisms 
are not always recoverable from the stool of patients with 
hemolytic uremic syndrome. Such organisms may trigger 
hemolytic uremic syndrome in patients with pre-existing 
complement dysregulation.10
In our patient, thrombotic microangiopathy resulting 
in ischemic bowel could have caused her diarrhea and 
hematochezia. In the absence of Shiga toxin in stool, 
  assessing a patient’s complement system function is appro-
priate.14 Our patient was on etanercept and an estrogen 
patch, both of which are potential endothelial offenders 
and   precipitants of atypical hemolytic uremic syndrome/ 
complement dysregulation.
eculizumab in atypical hemolytic  
uremic syndrome
Eculizumab, a high-affinity humanized monoclonal 
anti-C5 antibody, blocks terminal complement activity 
by binding to and blocking cleavage of the terminal 
complement protein, C5, into its proinflammatory, 
  prothrombotic, and lytic products: C5a and the cytotoxic 
membrane-attack complex, C5b-9. Upstream components 
of complement, most notably C3b, are left intact.3,17,18 In 
several case reports, eculizumab has been reported to be 
safe and effective in atypical hemolytic uremic syndrome, 
a condition of chronic systemic uncontrolled complement 
activation.3,17–27
The doses used in the current clinical trials of eculizumab 
in atypical hemolytic uremic syndrome are higher than the 
doses used in paroxysmal nocturnal hemoglobinuria.4–7 This 
seems reasonable, given the risk of multiorgan failure as a 
result of thrombotic microangiopathy in atypical hemolytic 
uremic syndrome.
Although no prospective controlled trials have been 
conducted, plasma exchange has historically been used to 
manage patients with atypical hemolytic uremic syndrome.28 
Plasma exchange generally must be used with high fre-
quency to stabilize the condition,24 and often loses   efficacy.16 
Additionally, plasma intervention has been associated with 
a 26% chance of major complications.29 Furthermore, 
compared with eculizumab, plasma exchange does not 
specifically treat the underlying defect in complement 
pathway regulation.28 Thus, eculizumab may prove to be 
more efficacious in the long term, and further investigation 
is warranted.
Complete and sustained terminal complement inhibition 
is considered necessary for adequate control of atypical 
hemolytic uremic syndrome. The optimal duration and 
frequency of therapy remains to be determined and varies 
among patients. For example, Nurnberger et al described 
an adult with relapsed atypical hemolytic uremic syndrome, 
despite a second kidney transplant, who maintained remission 
after only one dose of eculizumab 600 mg.17 Unfortunately,   Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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21 months later, this patient   suffered allograft loss after 
failing eculizumab retreatment for recurrence of atypical 
hemolytic uremic syndrome.14 In contrast, Gruppo et al 
described an infant with atypical hemolytic uremic syn-
drome refractory to plasma therapy, who required mainte-
nance eculizumab to sustain remission. The patient received 
eculizumab 300 mg weekly in three doses. Remission 
occurred 10 days after the first dose, and lasted for at least 
four months on maintenance eculizumab 600 mg every 
two weeks.25
Mache et al discussed eculizumab dosing for an adolescent 
with plasmapheresis-refractory atypical hemolytic uremic syn-
drome. An initial 600 mg was administered, and platelets nor-
malized in three days, haptoglobin normalized in five days, and 
renal function improved. Atypical hemolytic uremic syndrome 
relapsed two weeks after recovery of complement-mediated 
hemolytic activity. Treatment with 600 mg was repeated three 
times in six days, with only minor, transient improvement in 
renal function, and hemodialysis was ultimately required.1
Chatelet et al described the consequences of delaying 
the ninth dose of eculizumab in a renal transplant patient 
with recurrent atypical hemolytic uremic syndrome. The 
patient was on a maintenance dose of 1200 mg every 
14 days after receiving 900 mg weekly for four doses. They 
reported that a six-day delay in administering the ninth dose 
resulted in recurrent hemolysis and deterioration of trans-
plant function, necessitating resumption of eculizumab. 
The authors resumed eculizumab as permanent therapy for 
their patient, hypothesizing that the delayed dose caused 
complement breakthrough and relapse of thrombotic 
microangiopathy.20 Importantly, after 17 months of ecu-
lizumab therapy, acute thrombotic microangiopathy and 
hemolysis were controlled, renal function was maintained, 
and the need for blood transfusion decreased.2
Genetic abnormalities associated  
with atypical hemolytic uremic syndrome
Around 60% of atypical hemolytic uremic syndrome cases, 
both familial and sporadic, have been linked to genetic muta-
tions in complement regulatory proteins in the alternative 
complement pathway or autoantibodies to complement factor 
H (CFH).8,9 Consequently, we ordered genetic and antibody 
tests for our patient and the results are still pending. These 
tests are not required for diagnosis of atypical hemolytic 
uremic syndrome. Information on genetic abnormalities of 
the complement system as it relates to atypical hemolytic 
uremic syndrome can be obtained from two comprehensive 
papers by Norris and Remuzzi.8,9
Genetic testing is important in the care of patients with 
atypical hemolytic uremic syndrome because prognosis can 
vary depending on the gene mutations involved. For example, 
CFH mutations, with cardiac complications in 20% of cases, 
are associated with a worse long-term survival. CFH muta-
tions are associated with a 10-year survival rate of only 
40%–50% compared with cases of anti-CFH antibodies, CFI 
mutations, and C3 mutations, which have a 10-year survival 
rate of around 80%–90%. Furthermore, genetic testing pro-
vides the clinician with prognostic and predictive information 
about the disease course, treatment response, and long-term 
transplant outcome.8,9
Healthy carriers of CFH, MCP, or CFI mutations have 
an approximately 50% chance of developing atypical hemo-
lytic uremic syndrome. This suggests that complement gene 
mutations are predisposing rather than causative, and expres-
sion of atypical hemolytic uremic syndrome is dependent 
upon other genetic or environmental factors.1,8,9
Genetic testing is relevant in unaffected family members 
because mutation carriers can be monitored during conditions 
triggering complement activation, such as infections, drug 
exposures (including oral contraceptives), and pregnancy. 
Infections directly trigger the complement system. Drugs 
and pregnancy indirectly trigger complement activation by 
causing endothelial insult.8,9
Genetic testing is important for patients with atypical 
hemolytic uremic syndrome being considered for renal 
transplant. While outcomes of renal transplant vary depend-
ing on the genetic mutations, overall, there is a 50% rate 
of atypical hemolytic uremic syndrome recurrence in the 
allograft.8,9
Mutations of CFH, CFI, CFB and C3 are associated with 
post-transplant recurrence. This is because the mutations give 
rise to abnormalities in circulating proteins which mostly 
come from the liver, and thus can exist even after kidney 
transplant.8,9
In total, 80%–90% of patients with CFH and CFI 
mutations had allograft relapse following transplant. 
  Consequently, simultaneous liver-kidney transplant has 
been recommended for these patients.8,9 However, Zuber 
et al described pre-emptive plasma therapy and eculizumab 
as promising treatments which may reduce the need for 
simultaneous liver-kidney transplant.14
For patients with C3 mutations undergoing kidney trans-
plant, there is a 40%–50% risk of recurrence in the allograft. 
However, due to significant extrahepatic synthesis of C3, 
combined kidney-liver transplant is not recommended. 
  Furthermore, for patients with CFB mutations, isolated Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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kidney transplant and combined kidney-liver transplant is 
not recommended, because those patients are at increased 
surgical risk due to severe vascular disease.8,9
Conclusion
Eculizumab can safely reverse neurologic impairment and 
eliminate the need for dialysis in severe atypical hemolytic 
uremic syndrome. Because clinical trials are underway, the 
optimal duration of treatment with eculizumab remains to 
be determined. Although genetic abnormalities in comple-
ment regulatory factors or anti-CFH antibodies have been 
identified in approximately 60% of cases, genetic and 
antibody testing is not required for diagnosis of atypi-
cal hemolytic uremic syndrome.8,9 Because 20%–30% of 
atypical hemolytic uremic syndrome cases present with 
diarrhea, this presenting symptom alone cannot be used 
to distinguish atypical and enteropathic hemolytic uremic 
syndrome.14
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